绝经前激素受体阳性乳腺癌内分泌治疗现状

doi:10.11904/j.issn.1002-3070.2017.02.015

Abstract

Abstract: Endocrine therapy is one of the important treatments of adjuvant therapy among patients with positive hormone receptor breast cancer.In the endocrine therapy setting,5 years of tamoxifen therapy has been the standard treatment regimen for premenopausal patients.In recent years,this standard has been challenged.The results of many large randomized clinical trials have made a new choice for adjuvant endocrine therapy in premenopausal patients.In this paper,we review the present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer.

Key words: Breast cancer, Premenopausal, Endocrine therapy

CLC Number:

R246.5

SHI Lei,XU Peiquan. The present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 170-174.

References

1 Lei F,Kathrin S,Jun J,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):279-289.
2 Siegel R,Naishadham D,Jemal A.Cancer statistics 2013[J].CA Cancer J Clin,2013,63(1):11-30.
3 荆长军,魏海霞.复发转移性乳腺癌的内分泌治疗策略[J].临床合理用药,2013,6(8):177-178.
4 Ye S,Sae J,Yeon S,et al.MiRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer[J].Oncotarget,2016,7(27):42261-42262.
5 Kathrin S,Tanja B,Lei F,et al.Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer[J].The Breast,2013,22(3):171-175.
6 Yu K,Wu J,Shen Z,et al.Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis:implication for extended endocrine therapy[J].Clin Endocrinol Metab,2012,97(12):2201-2209.
7 He M,Tang L,Yu K,et al.Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer[J].Eur J Surg Oncol,2012,38(11):1022-1028.
8 Montemurro F,Del M,De L,et al.Endocrine therapy in premenopausal women with breast cancer:a critical appraisal of current evidence[J].Expert Review of Anticancer Therapy,2016,16(2):211-218.
9 Davies C,Pan H,Godwin J,et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J].Lancet,2013,381(9869):805-816.
10 Gray R,Rea D,Handley K,et al.ATTom:long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J].Clin Oncol,2013,31(18):2631-2632.
11 Li J,Shao Z.Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer:selecting the best agents,the timing and duration of treatment[J].Chin Clin Oncol,2016,5(3):1-12.
12 中国乳腺癌内分泌治疗专家共识专家组.中国乳腺癌内分泌治疗专家共识(2015年版)[J].中国癌症杂志,2015,25(9):755-759.
13 Gu R,Jia W,Zeng Y,et al.A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients:a retrospective cohort study[J].BMC Cancer,2012,12(1):1-10.
14 Souhami L,Bae K,Pilepich M,et al.Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy:a secondary analysis of RTOG 85-31[J].J Clin Oncol,2009,27(13):2137-2143.
15 Aleksander C,Serena W,Deborah T.Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer[J].ASCO Educationcal Book,2014,34(1):12-15.
16 Goldhirsch A,Wood W,Coates A,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
17 Tevaarwerk A,Wang M,Zhao F,et al.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative,hormone receptor-positive breast cancer(E-3193,INT-0142):a trial of the Eastern Cooperative Oncology Group[J].Clin Oncol,2014,32(35):3948-3958.
18 Francis P,Regan M,Fleming G,et al.Adjuvant ovarian suppression in premenopausal breast cancer[J].N Engl J Med,2015,372(5):436-446.
19 Mathew A,Davidson N.Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer[J].Breast,2015,24(2):120-125.
20 Marco C,Elisabetta M.Picking the optimal endocrine adjuvant treatment for pre-menopausal women[J].Breast,2015,24(2):11-14.
21 Lorenzo R,Olivia P.The Modern landscape of endocrine therapy for premenopausal women with breast cancer[J].Breast Care,2015,10(5):312-315.
22 Burstein H,Lacchetti C,Anderson H,et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer:American society of clinical oncology clinical practice guideline update on ovarian suppression[J].Clin Oncol,2016,34(10):1689-1701.
23 Saranya C.Clinical utilities of aromatase inhibitors in breast cancer[J].Int J Womens Health,2014,7(2):493-499.
24 杨梅.他莫昔芬与来曲唑在绝经后乳腺癌辅助内分泌治疗中临床对比研究[J].海南医学院学报,2016,22(9):910-912.
25 Bernhard J,Luo W,Ribi K,et al.Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT):a combined analysis of two phase 3 randomised trials.[J].Lancet Oncol,2015,16(7):848-858.
26 Cossetti R,Tyldesley S,Speers C,et al.Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008[J].Clin Oncol,2015,33(1):65-73.
27 Pagani O,Regan M,Walley B,et al.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J].N Engl J Med,2014,371(2):107-118.
28 Ribeiro J,Cardoso MJ.Highlights from the Tenth European Breast Cancer Conference(EBCC10),Amsterdam,9-11 March 2016[J].Ecancer medical science,2016,10:644.
29 李卉,张翠英,王珏,等.乳腺癌的内分泌治疗研究进展[J].内蒙古医学杂志,2012,44(1):64-68.
30 Meng Z,Ramaswamy B.Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer[J].World J Clin Oncol,2014,5(3):248-262.
31 Oesterreich S,Davidson NE.The search for ESR1 mutations in breast cancer[J].Nat Genet,2013,45(12):1415-1416.
32 廖宁.启示与创新-展望2015年乳腺癌辅助内分泌治疗[J].循证医学,2015,15(3):134-137.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[4]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[5]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[6]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[7]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[8]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[9]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[10]	ZHENG Wei, XU Shouping, PANG Da. Expression,prognosis and function of long chain non-coding RNA-Linc00152 in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 7-13.
[11]	YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.
[12]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[13]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.
[14]	LI Hongyang, SUN Liang, JIANG Xing, YUAN Guangjun, LIU Yan. Dauricine enhances the sensitivity of 5-fluorouracil in human breast cancer MCF-7 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 385-389.
[15]	LUO Jianing, HAO Chuncheng, ZHANG Jianxin, LU Jiangyue, GE Xiaofeng. Effect of postoperative adjuvant radiotherapy on prognosis of triple-negative breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 411-416.

The present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments